Anergen, N. V. Organon deal

The companies agreed to develop a rheumatoid arthritis product using an Organon peptide with ANRG's AnergiX technology. ANRG will receive up to $15 million, including a license fee, milestones and R&D funding. The bulk of the payments will be received over the next three years. Organon will receive worldwide marketing rights and ANRG will receive royalties.

Organon's compound is a cartilage-derived arthritogenic protein. The Dutch company may substitute other peptides for development and will receive exclusivity for AnergiX products in the field of rheumatoid arthritis through the completion of the initial clinical trial. ...